Literature DB >> 7756383

Immunobiology and immunotherapy of melanoma.

B Mukherji1, N G Chakraborty.   

Abstract

The immunobiology of melanoma has dominated the investigative field in tumor immunology. Indeed, the best evidence of immunogenicity of a spontaneously grown human cancer has been found in this model. Yet considerable doubt has lingered on the very issue of tumor immunity in general and on the subject of melanoma immunity as well. To a great extent, the doubt has persisted mostly because of our past inability to define a true tumor antigen. Fortunately, the human melanoma model has given us a remarkable insight into what had been one of the most tenaciously elusive issues in tumor immunology, namely, the structural definition of "tumor antigens": the raison d'être for tumor immunology. This review is confined to the areas of structural definition of melanoma antigens and to the topic of cellular immunity to melanoma because most of the recent findings have occurred in these areas. The topic of melanoma immunotherapy and novel opportunities for immunotherapy in this disease is also discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7756383     DOI: 10.1097/00001622-199503000-00014

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  9 in total

Review 1.  Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy.

Authors:  Arvind Chhabra
Journal:  Vaccine       Date:  2010-05-06       Impact factor: 3.641

2.  Optimised electroporation mediated DNA vaccination for treatment of prostate cancer.

Authors:  Sarfraz Ahmad; Garrett Casey; Paul Sweeney; Mark Tangney; Gerald C O'Sullivan
Journal:  Genet Vaccines Ther       Date:  2010-02-05

3.  A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.

Authors:  F M Batliwalla; B A Bateman; D Serrano; D Murray; S Macphail; V C Maino; J C Ansel; P K Gregersen; C A Armstrong
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

4.  Porcine splenic peptides (Polyerga) decrease the number of experimental lung metastases in mice.

Authors:  M Jurin; N Zarković; Z Ilić; S Borović; M Hartleb
Journal:  Clin Exp Metastasis       Date:  1996-01       Impact factor: 5.150

5.  Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes.

Authors:  Cristina Maccalli; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

6.  Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings.

Authors:  E Tartour; M Mehtali; X Sastre-Garau; I Joyeux; C Mathiot; J M Pleau; P Squiban; C Rochlitz; M Courtney; P Jantscheff; R Herrmann; P Pouillart; W H Fridman; T Dorval
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

7.  The in vitro and in vivo anti-melanoma effects of hydroxyapatite nanoparticles: influences of material factors.

Authors:  Hongfeng Wu; Zhongtao Li; Jiaoqing Tang; Xiao Yang; Yong Zhou; Bo Guo; Lin Wang; Xiangdong Zhu; Chongqi Tu; Xingdong Zhang
Journal:  Int J Nanomedicine       Date:  2019-02-15

Review 8.  New Developments in T Cell Immunometabolism and Implications for Cancer Immunotherapy.

Authors:  Nathaniel Oberholtzer; Kristen M Quinn; Paramita Chakraborty; Shikhar Mehrotra
Journal:  Cells       Date:  2022-02-17       Impact factor: 6.600

9.  On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases.

Authors:  M R Bernsen; L Håkansson; B Gustafsson; L Krysander; B Rettrup; D Ruiter; A Håkansson
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.